water) test was performed for 0.5 h
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
In a study, researchers used a GIP receptor antagonist antibody (GIPRAb) and a GLP- 1 receptor agonist to target both pathways [81]
What are GLP-1 Medications
Researchers looked at data from 46,000 patients who had received a GLP-1 drug for at least six months, compared with 92,000 patients who had not taken these drugs
The Ministry of Food and Drug Safety (MFDS) is closely watching whether the recent reports about the possibility of glucagon-like peptide 1 (GLP-1) treatments causing suicidal or self-harming thoughts will also affect Korean patients